AU7756494A - Substituted heterocyclic carboxamides, their preparation andtheir use as pharmaceuticals - Google Patents
Substituted heterocyclic carboxamides, their preparation andtheir use as pharmaceuticalsInfo
- Publication number
- AU7756494A AU7756494A AU77564/94A AU7756494A AU7756494A AU 7756494 A AU7756494 A AU 7756494A AU 77564/94 A AU77564/94 A AU 77564/94A AU 7756494 A AU7756494 A AU 7756494A AU 7756494 A AU7756494 A AU 7756494A
- Authority
- AU
- Australia
- Prior art keywords
- preparation
- pharmaceuticals
- substituted heterocyclic
- heterocyclic carboxamides
- andtheir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
The invention relates to compounds of the formula I <IMAGE> a process for their preparation, and their use as medicaments. In particular, the compounds are employed for the inhibition of collagen biosynthesis, as inhibitors of proline hydroxylase and as fibrosuppressants.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4337271 | 1993-11-02 | ||
DE4337271A DE4337271A1 (en) | 1993-11-02 | 1993-11-02 | ubstd. heterocyclic carboxylic acid amides and their prepn. |
DE19944410881 DE4410881A1 (en) | 1994-03-29 | 1994-03-29 | Substd. heterocyclic carboxylic acid amides and their prepn. |
DE4410881 | 1994-03-29 | ||
DE19944433928 DE4433928A1 (en) | 1994-09-23 | 1994-09-23 | Substd. heterocyclic carboxylic acid amides and their prepn. |
DE4433928 | 1994-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7756494A true AU7756494A (en) | 1995-05-18 |
AU676775B2 AU676775B2 (en) | 1997-03-20 |
Family
ID=27205714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU77564/94A Ceased AU676775B2 (en) | 1993-11-02 | 1994-10-31 | Substituted heterocyclic carboxamides, their preparation andtheir use as pharmaceuticals |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0650961B1 (en) |
JP (1) | JPH07228571A (en) |
KR (1) | KR950014072A (en) |
CN (1) | CN1107145A (en) |
AT (1) | ATE149486T1 (en) |
AU (1) | AU676775B2 (en) |
CA (1) | CA2134866A1 (en) |
CY (1) | CY2120B1 (en) |
CZ (1) | CZ289356B6 (en) |
DE (1) | DE59401924D1 (en) |
DK (1) | DK0650961T3 (en) |
ES (1) | ES2101421T3 (en) |
GR (1) | GR3023174T3 (en) |
HK (1) | HK1006711A1 (en) |
IL (1) | IL111454A (en) |
MY (1) | MY112413A (en) |
NO (1) | NO301880B1 (en) |
NZ (1) | NZ264821A (en) |
PL (1) | PL179794B1 (en) |
TW (1) | TW399046B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides |
DE19746287A1 (en) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments |
FR2803592A1 (en) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | NOVEL DERIVATIVES OF 3-HYDROXYPICOLINIC ACID, PROCESS FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME |
DE10123573B4 (en) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamide derivatives and their use as pharmaceuticals |
DE10123587B4 (en) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamide derivatives and their use as pharmaceuticals |
ES2261693T3 (en) | 2001-05-08 | 2006-11-16 | Schering Aktiengesellschaft | DERIVATIVES OF CIANOANTRANILAMIDA AND ITS EMPLOYMENT AS MEDICINES. |
CN101664408B (en) * | 2001-12-06 | 2013-05-01 | 法布罗根股份有限公司 | Stabilization of hypoxia inducible factor (HIF) alpha |
EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
US20030153503A1 (en) | 2001-12-06 | 2003-08-14 | Klaus Stephen J. | Methods of increasing endogenous erythropoietin (EPO) |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
CN102977015B (en) * | 2003-06-06 | 2015-05-06 | 菲布罗根有限公司 | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
JP4792048B2 (en) | 2005-03-02 | 2011-10-12 | ファイブロゲン インコーポレイティッド | Thienopyridine compounds and methods of use thereof |
US20060276477A1 (en) * | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
KR20080028918A (en) | 2005-06-15 | 2008-04-02 | 피브로겐, 인크. | Compounds and methods for treatment of cancer |
CN103382216B (en) | 2006-01-27 | 2016-04-20 | 菲布罗根有限公司 | Make the Cyanoisoquinoline compound that hypoxia inducible factor (HIF) is stable |
CA2647596C (en) | 2006-04-04 | 2012-06-12 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
ES2705587T3 (en) | 2006-06-26 | 2019-03-26 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
WO2009002533A1 (en) | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
ES2360929T3 (en) * | 2007-09-20 | 2011-06-10 | Amgen Inc. | ACID DERIVATIVES 1- (4- (4-BENCILBENZAMIDO) -BENCIL) AZETIDIN-3-CARBOXYL AND RELATED COMPOUNDS AS MODULATORS OF THE S1P RECEPTOR FOR THE TREATMENT OF IMMUNE DISORDERS. |
WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
KR101007674B1 (en) * | 2010-08-13 | 2011-01-13 | 김병두 | High velocity oxygen fuel spray gun with auxiliary cap and the spray system |
KR101007675B1 (en) * | 2010-08-13 | 2011-01-13 | 김병두 | Plasma spray gun with auxiliary cap and plasma spray system using the same |
NO2686520T3 (en) | 2011-06-06 | 2018-03-17 | ||
EP2834220B1 (en) | 2012-03-09 | 2016-11-09 | Fibrogen, Inc. | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors |
BR112014032873B1 (en) | 2012-07-04 | 2019-02-12 | Agro-Kanesho Co., Ltd. | 2-AMINONICOTINIC ACID ESTER DERIVATIVE, AND, BACTERICIDE |
CN107540607A (en) | 2012-07-16 | 2018-01-05 | 菲布罗根有限公司 | The crystal habit of prolyl hydroxylase inhibitors |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
MY171483A (en) | 2012-07-16 | 2019-10-15 | Fibrogen Inc | Process for making isoquinoline compounds |
RU2666144C2 (en) | 2013-01-24 | 2018-09-06 | Фиброген, Инк. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
KR20220164069A (en) | 2013-06-06 | 2022-12-12 | 피브로겐, 인크. | Pharmaceutical formulations of a hif hydroxylase inhibitor |
ES2974273T3 (en) | 2013-06-13 | 2024-06-26 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
TWI665190B (en) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
CN106146395B (en) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3- hydroxypyridine compound, preparation method and its pharmaceutical applications |
HUE056958T2 (en) | 2015-04-01 | 2022-04-28 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
US20210206765A1 (en) * | 2018-09-13 | 2021-07-08 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4015255A1 (en) | 1990-05-12 | 1991-11-14 | Hoechst Ag | OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE |
EP0541042A1 (en) * | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | 2,4- and 2,5-pyridine-dicarboxylic acid derivatives, process for their preparation and their use |
EP0633881B1 (en) * | 1992-03-11 | 2003-10-29 | Narhex Limited | Amine derivatives of oxo- and hydroxy-substitued hydrocarbons |
TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
-
1994
- 1994-10-27 EP EP94117018A patent/EP0650961B1/en not_active Expired - Lifetime
- 1994-10-27 ES ES94117018T patent/ES2101421T3/en not_active Expired - Lifetime
- 1994-10-27 DK DK94117018.5T patent/DK0650961T3/en active
- 1994-10-27 DE DE59401924T patent/DE59401924D1/en not_active Expired - Fee Related
- 1994-10-27 AT AT94117018T patent/ATE149486T1/en not_active IP Right Cessation
- 1994-10-28 PL PL94305646A patent/PL179794B1/en unknown
- 1994-10-30 IL IL11145494A patent/IL111454A/en not_active IP Right Cessation
- 1994-10-31 NZ NZ264821A patent/NZ264821A/en unknown
- 1994-10-31 MY MYPI94002894A patent/MY112413A/en unknown
- 1994-10-31 AU AU77564/94A patent/AU676775B2/en not_active Ceased
- 1994-11-01 NO NO944162A patent/NO301880B1/en not_active IP Right Cessation
- 1994-11-01 CA CA002134866A patent/CA2134866A1/en not_active Abandoned
- 1994-11-01 CZ CZ19942683A patent/CZ289356B6/en not_active IP Right Cessation
- 1994-11-02 KR KR1019940028871A patent/KR950014072A/en not_active Application Discontinuation
- 1994-11-02 CN CN94117623A patent/CN1107145A/en active Pending
- 1994-11-02 JP JP6292032A patent/JPH07228571A/en not_active Abandoned
- 1994-12-05 TW TW083111257A patent/TW399046B/en not_active IP Right Cessation
-
1997
- 1997-04-18 GR GR970400831T patent/GR3023174T3/en unknown
-
1998
- 1998-06-22 HK HK98105872A patent/HK1006711A1/en not_active IP Right Cessation
- 1998-09-29 CY CY9800039A patent/CY2120B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MY112413A (en) | 2001-06-30 |
NO944162L (en) | 1995-05-03 |
IL111454A (en) | 2001-08-08 |
NO944162D0 (en) | 1994-11-01 |
ES2101421T3 (en) | 1997-07-01 |
CY2120B1 (en) | 2002-04-26 |
CZ289356B6 (en) | 2002-01-16 |
IL111454A0 (en) | 1994-12-29 |
ATE149486T1 (en) | 1997-03-15 |
TW399046B (en) | 2000-07-21 |
CA2134866A1 (en) | 1995-05-03 |
GR3023174T3 (en) | 1997-07-30 |
DK0650961T3 (en) | 1997-09-15 |
DE59401924D1 (en) | 1997-04-10 |
HK1006711A1 (en) | 1999-03-12 |
CN1107145A (en) | 1995-08-23 |
PL179794B1 (en) | 2000-10-31 |
KR950014072A (en) | 1995-06-15 |
PL305646A1 (en) | 1995-05-15 |
CZ268394A3 (en) | 1995-05-17 |
EP0650961A1 (en) | 1995-05-03 |
EP0650961B1 (en) | 1997-03-05 |
NZ264821A (en) | 1997-02-24 |
AU676775B2 (en) | 1997-03-20 |
NO301880B1 (en) | 1997-12-22 |
JPH07228571A (en) | 1995-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7756494A (en) | Substituted heterocyclic carboxamides, their preparation andtheir use as pharmaceuticals | |
AU7756694A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | |
AU697015B2 (en) | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | |
AP9801237A0 (en) | Quinoline derivatives. | |
AU6718494A (en) | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase | |
AU2055500A (en) | Aromatic amides | |
AU2672995A (en) | {a}-annelated pyrrole derivatives and pharmaceutical uses thereof | |
CA2218663A1 (en) | Benzisoxazole and indazole derivatives as antipsychotic agents | |
AU6602394A (en) | New alpha-amino acid compounds, a process for the preparation thereof and pharmaceutical compositions containing them | |
AU3559793A (en) | New 3-aminochroman spiro compounds, processes for their preparation and pharmaceutical compositions containing them | |
AU6991696A (en) | 3-beta-aminoazabicyclo-octane or -nonane naphthamide derivatives as antipsychotic agents | |
AU6970394A (en) | Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2 | |
WO1995022544A3 (en) | Substituted 1,3,8-triaza-spiro(4,5)-decan-4-one derivatives useful as preliminary stages in the production of pharmaceuticals | |
MY112414A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | |
AU5618699A (en) | N-substituted azabicycloheptane derivatives, production and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |